Neurotoxicity characterization phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- Acronyms Neurabrax
- 28 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 07 May 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.